ABL1 and acute lymphoblastic leukemia: In this study, we measured PARP1 expression levels in cell models representative of acute lymphoblastic malignancies and aimed to investigate the efficacy of AZD2461 in inhibiting cell growth, inducing cell death as well as modulating biomarker expression in a model of ALL with BCR::ABL1 p190+ isoform, comparing the cytotoxicity profiles of AZD2461 with imatinib, the BCR::ABL1 inhibitor which is a gold-standard in the clinical practice for the treatment of Ph+ tumors.